225 related articles for article (PubMed ID: 18424894)
1. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
Rossi D; Catalano G
Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894
[No Abstract] [Full Text] [Related]
2. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling.
Mangili G; Petrone M; Gentile C; De Marzi P; Viganò R; Rabaiotti E
Gynecol Oncol; 2008 Feb; 108(2):332-5. PubMed ID: 18083217
[TBL] [Abstract][Full Text] [Related]
3. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
4. The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia.
Kanis M; Kesterson JP; Lele S
Eur J Gynaecol Oncol; 2009; 30(4):387-8. PubMed ID: 19761128
[TBL] [Abstract][Full Text] [Related]
5. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
[TBL] [Abstract][Full Text] [Related]
6. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
[TBL] [Abstract][Full Text] [Related]
7. ["Hand-foot" syndrome--after liposomal pegylated doxorubicin in patients with the ovarian cancer recurrence (own experiences)].
Mrochen-Domin I; Nowara E; Kaleta B
Ginekol Pol; 2008 May; 79(5):332-7. PubMed ID: 18624107
[TBL] [Abstract][Full Text] [Related]
8. "Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome".
Von Moos R; Cathomas R
Eur J Dermatol; 2009; 19(3):264-5. PubMed ID: 19213658
[No Abstract] [Full Text] [Related]
9. Distal phalange necrosis: a severe manifestation of palmar plantar erythrodysesthesia.
Palaia I; Angioli R; Bellati F; Basile S; Rabitti C; Panici PB
Am J Obstet Gynecol; 2006 Oct; 195(4):e1-2. PubMed ID: 16875651
[TBL] [Abstract][Full Text] [Related]
10. Palmar-plantar erythrodysaesthesia and non-pegylated liposomal doxorubicin. A case study.
Tamayo-Orbegozo E; Iruin-Sanz A; Oñate-Muzás E; Segrelles-Bellmunt G
Farm Hosp; 2011; 35(1):46-7. PubMed ID: 20619714
[No Abstract] [Full Text] [Related]
11. Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.
Mangana J; Zipser MC; Conrad C; Oberholzer PA; Cozzio A; Knuth A; French LE; Dummer R
Eur J Dermatol; 2008; 18(5):566-70. PubMed ID: 18693162
[TBL] [Abstract][Full Text] [Related]
12. Hand-foot syndrome related to liposomal doxorubicin.
Swenson KK; Bell EM
Oncol Nurs Forum; 2010 Mar; 37(2):137-9. PubMed ID: 20189920
[No Abstract] [Full Text] [Related]
13. The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma.
Molpus KL; Anderson LB; Craig CL; Puleo JG
Gynecol Oncol; 2004 May; 93(2):513-6. PubMed ID: 15099971
[TBL] [Abstract][Full Text] [Related]
14. [Liposomal doxorubicin and palmoplantar erythrodysesthesia].
Tomb R; Stephan F; Halaby G
Ann Dermatol Venereol; 2003 Nov; 130(11):1057-8. PubMed ID: 14724543
[No Abstract] [Full Text] [Related]
15. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
von Moos R; Thuerlimann BJ; Aapro M; Rayson D; Harrold K; Sehouli J; Scotte F; Lorusso D; Dummer R; Lacouture ME; Lademann J; Hauschild A
Eur J Cancer; 2008 Apr; 44(6):781-90. PubMed ID: 18331788
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced palmer planter erythrodysesthesia.
Bhasin S; Sunita ; Gupta DK; Kataria SP; Saluja S; Sharma M
J Assoc Physicians India; 2005 Feb; 53():155-6. PubMed ID: 15847041
[TBL] [Abstract][Full Text] [Related]
17. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
Webster-Gandy JD; How C; Harrold K
Eur J Oncol Nurs; 2007 Jul; 11(3):238-46. PubMed ID: 17350337
[TBL] [Abstract][Full Text] [Related]
18. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
[TBL] [Abstract][Full Text] [Related]
19. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia.
Martschick A; Sehouli J; Patzelt A; Richter H; Jacobi U; Oskay-Ozcelik G; Sterry W; Lademann J
Anticancer Res; 2009 Jun; 29(6):2307-13. PubMed ID: 19528496
[TBL] [Abstract][Full Text] [Related]
20. Histologic patterns of polyethylene glycol-liposomal doxorubicin-related cutaneous eruptions.
Cady FM; Kneuper-Hall R; Metcalf JS
Am J Dermatopathol; 2006 Apr; 28(2):168-72. PubMed ID: 16625083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]